4 展望

　　对于AR，还存在很多未知因素，其复杂性和群体特征性是并存的，需进一步深入研究。在研究AR及临床防治AR时，应在考虑其复杂性的基础上，兼顾群体差别性，区别地辨证地对待这种现象，针对不同的群体制定不同的研究方案，为不同的个体制定更有效的治疗策略，使个体化治疗得到更高层次的体现。比如，我们可根据挟杂危险因素的不同来划分不同的群体，通过研究这些不同群体中AR产生的机理，相应地揭示其可能的群体特征。目前，关于AR的研究还不够全面，不够系统，也存在很多争议，结合中医中药，针对不同的群体进行AR的产生机理及防治方面的研究是一条值得探索之路。

【参考文献】
  　1 Sztriha LK， Sas K， Vecsei L. Aspirin resistance in stroke: 2004. J Neurol Sci. 2005; （229-230）: 163-169.

　　2 Weber ZZ， Zimmermann KC， Meyer-Kirchrath J， et al. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet. 1999; 353: 900.

　　3 Weber AA， Przytulski B， Schumacher M， et al. Flow cytometry analysis of platelet cyclooxygenase-2 expression: induction of platelet cyclooxygenase-2 in patients under-going coronary artery bypass grafting. Br J Haematol. 2002; 117（2）: 424-426.

　　4 Rocca B， Secchiero P， Ciabattoni G， et al. Cyclooxyge-nase-2 expression is induced during human megakaryo-poiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA. 2002; 99: 7634-7639.

　　5 Kimmel SE， Berlin JA， Reilly M， et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med. 2005; 142（3）: 157-164.

　　6 Johnsen SP， Larsson H， Tarone RE， et al. Risk of hospitalization for myocardial infarction among users of rofecoxib， celecoxib， and other NSAIDs: a population-based case-control study. Arch Intern Med. 2005; 165（9）: 978-984.

　　7 Nurtjahja-Tjendraputra E， Ammit AJ， Roufogalis BD， et al. Effective anti-platelet and COX-1 enzyme inhibi-tors from pungent constituents of ginger. Thromb Res. 2003; 111（4-5）: 259-265.

　　8 Catella-Lawson F， Reilly MP， Kapoor SC， et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001; 345（25）: 1809-1817.

　　9 Cryer B， Berlin RG， Cooper SA， et al. Double-blind， randomized， parallel， placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy adult volunteers. Clin Ther. 2005; 27（2）: 185-191.

　　10 Kong DF. Aspirin in cardiovascular disorders. What is the optimum dose? Am J Cardiovasc Drugs. 2004; 4（3）: 151-158.

　　11 Helgason CM， Tortorice KL， Winkler SR， et al. Aspi-rin response and failure in cerebral infarction. Stroke. 1993; 24（3）: 345-350.

　　12 Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death， myocardial infarction， and stroke in high risk patients. BMJ. 2002; 324（7329）: 71-86.

　　13 Cox D， Maree AO， Dooley M， et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin inhealthy volunteers. Stroke. 2006; 37（8）: 2153-2158

　　14 Macchi L， Christiaens L， Brabant S， et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res. 2002; 107（1-2）: 45-49.

　　15 Christiaens L， Macchi L， Herpin D， et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res. 2002; 108（2-3）: 115-119.

　　16 Mattiasson I， Lethagen S， Hillarp A. Increased sensi-tivity to ADP-aggregation in aspirin treated patients with recurrent ischemic stroke? Int Angiol. 2003; 22（3）: 239-242.

　　17 Payne DA， Jones CI， Hayes PD， et al. Platelet inhibi-tion by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance? Thromb Haemost. 2004; 92（1）: 89-96.

　　18 Mirkhel A， Peyster E， Sundeen J， et al. Frequency of aspirin resistance in a community hospital. Am J Cardi-ol. 2006; 98（5）: 577-579.

　　19 Macchi L， Christiaens L， Brabant S， et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 （GP IIIa） polymorphism but not with C807T （GP Ia/IIa） and C-5T Kozak （GP Ibalpha） polymorphisms. J Am Coll Cardiol. 2003; 42（6）: 1115-1119.

　　20 Gum PA， Kottke-Marchant K， Poggio ED， et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001; 88（3）: 230-235.

　　21 Jagroop IA， Mikhailidis DP. Doxazosin， an alpha1- adrenoceptor antagonist， inhibits serotonin-induced shape change in human platelets. J Hum Hypertens. 2001; 15（3）: 203-207.

上一页  [1] [2]